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Microvasculature is essential to connect main blood vessels to smaller capillary 
networks throughout the body. As with all vasculature, these structures can be impaired 
due to disease or injury, and their reconstruction is imperative to ensure the patient’s 
health. However, most regeneration studies to date have focused on inducing or 
engineering either small capillary beds or large arteries and veins. Previously we 
developed a system to study microvasculature development guided on electrospun fibrin 
hydrogel microfibers. The focus of this work was to utilize this biomaterial to develop 
freestanding perfusable microvascular structures, a feat that has not been achieved to 
date. Progenitor endothelial cells and vascular smooth muscle cells were seeded onto 
microfibers to create a robust cell layer before applying a degradation treatment to 
remove the microfiber core, creating a perusable structure. We used this seeding protocol  
on three different set ups throughout the study to create our microvascular structures. The 
first set up relied on the scaffold using a frame for support. The scaffolds on frames were 
used to test if the cell layers would be damaged by the degradation treatments, which 
were then used to achieve luminal formation. When lumen formation was created without 
damage to the cell layers, we conducted the second set of experiments in two different 
devices. These devices allowed the scaffold to be freestanding and to support the growth 
of a robust cell layer. However, full degradation of the scaffold could not be obtained on 
cellularized microfibers due to a thick cell layer that prevented plasmin diffusion. 
Therefore, the shape of the microfibers was altered to allow direct perfusion via a hollow 
structure. With the use of direct perfusion, the hollow microfibers allowed for a cellular 
structure to grow with a distinct lumen. This engineered microvasculature has the 
 iii 
potential of creating patient specific perusable structures for cell therapy and drug 
delivery testing. 
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One of the main hurdles in tissue engineering is the need for reconstructing 
various types of complex structures with specific macroscopic geometries and also 
detailed microscopic features.  Microvasculature is essential to the human body for it 
connects the smallest system within the blood vessel network (the capillary beds) to 
larger arteries and veins. Its main function is to distribute blood to various tissues 
throughout the body and is required for nutrient, gas, and waste diffusion between the 
blood and the cellular and matrix components of vascularized tissues[1].  
Microvasculature is a multi-layered tissue in which there is an endothelial inner layer and 
an outer layer composed of vascular smooth muscle cells, and their corresponding 
extracellular matrix (ECM). The inner layer of endothelial cells responds to the flow 
regime of blood and is aligned with the direction of flow. There are many types of 
microvasculature, which include the commonly known arterioles, venules, as well as 
metarterioles — which link arterioles and capillaries[1].  
The need to engineer microvasculature has increased due to a rise in vascular 
diseases as well as accidents that can cause a breakage of vasculature. Considering these 
reasons, many different approaches have been taken to begin the construction of these 
microvascular structures. One of the first approaches was to use microfluidic devices to 
try to mimic the shear stress conditions within the vessels [2-5]. However, a drawback of 
these systems is that their cross section is rectangular, not fully mimicking the 
vasculature in the body. Other techniques used to create microvasculature are three-
dimensional (3D) printing, where cells are directly deposited on substrates such as 
collagen gels to copy three dimensional microvasculature[6]. Another technique used is 
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to create the structures with the help of biomaterials such as collagen gels, a process that 
involves the use of polymers to create a basis for which cells can adhere and grow within 
and later degrade naturally in the body[7-9]. 
Once these approaches to the construction are stable, the structures created can 
then be used for various applications. A common use is for drug testing and delivery to 
drug through microvasculature walls. However, none of the methods mentioned above 
can be used for another application that has a lot of potential; microsurgical implantation. 
Tissue-engineered blood vessel surgical bypass has become popular for treatment of 
peripheral vascular diseases[7]. The approach used for these studies, the use of a scaffold 
to create microvasculature, is able to create structures that can be biocompatibility 
implanted without waiting for integration and angiogenesis. This use of the reconstructed 
microvasculature is highly looked upon because it reduces the chances of the body 
rejecting the final product because the main components used can be harvested from the 




 Microvasculature is a complex multi-layered tissue that consists of various 
different proteins and cell types, each of which play a significant role in the mechanical 
behavior of the structure[10]. Each individual vessel is composed of three layers; the 
intima, the media, and the adventitia. The intima is the innermost layer of microvascular 
tissue and is constantly in contact with the bloodstream and provides a critical barrier to 
platelet activation.  Endothelial cells comprise the first section of the layer, which lay on 
a thin basal lamina, and a subendothelial layer made of ECM proteins, mainly fibronectin 
and type IV collagen [11]. The media layer is the thickest of the three and is made up of 
many stratums of smooth muscle cells within a matrix of various extracellular proteins, 
such as elastin and collagen I and III [12]. The outermost layer of microvasculature, the 
adventitia, is made up of collagen I and fibroblasts which are randomly arranged 
throughout the layer[12]. However, adventitia is usually only present in the larger class 
vessels. 
The collagen and elastin present throughout the microvasculature are essential to 
the tissue because they provide tensile support, prevent ruptures, and confer elasticity to 
the vessel, allowing the ability to recover from potential ruptures or deformations[13]. 
The elastin’s elastic nature across the span of the tissue controls the low strain 
mechanical response of the vessel to the flow regime of blood and also prevents energy 
from being dissipated as heat.  
 Fluid shear stress is also a major influence in the structure of microvasculature, 
for it helps create or destroy the formation of the tissue[8, 14]. For example, when 
microvasculature is exposed to laminar shear stress, there is a promotion of endothelial 
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cell quiescence, as well as an alteration of gene expression, a change in thrombotic 
potential, a promotion of anti-inflammatory phenotype, and an induction of flow 
alignment of the endothelial cells in the intima. However, when the intima is exposed to 
turbulent flow, the opposite occurs due to the harsh nature of the fluid at that state[8]. In 
many vessels, the shear stress contributes significantly to the vascular tone and structural 
adaptation through the endothelial cell dependent mediators[15]. Additionally, the use of 
fluid shear stress is used to help align certain ECM proteins such as elastin. 
For the intent of this series of experiments, we desire to obtain microvasculature 
with an inner diameter of about 250 µm and a wall thickness of approximately 30 µm.  In 
order to develop microvascular structures with the correct cellular and ECM composition 
and organization, we utilize endothelial progenitor cells (EPCs) and vascular smooth 
muscle cells (vSMCs). EPCs, isolated in either adult peripheral or umbilical cord blood, 
originate from the bone marrow and circulate throughout the blood stream. These cells 
are advantageous to use for angiogenic therapies or as biomarkers to assess 
cardiovascular disease progression because they have the ability to proliferate and 
generate functional offspring[16, 17]. ECFCs, a subtype of EPCs derived from umbilical 
cord blood, are used as the basis for the intima instead of other endothelial cells because 
of their many robust vasculogenic properties and proliferative potential[16]. 
Microfibers 
Fibrinogen is a glycoprotein that is 340 kDa and is synthesized in the liver[10]. It 
is also found freely circulating in the bloodstream because it is one of the main 
components of blood clots. This creates a large abundance of fibrin in the body, making it 
easy to cultivate and use for patient specificity. During coagulation, fibrinogen is cleaved 
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by thrombin to form fibrin. Fibrin then forms lateral protofibril association, which results 
in the formation of a loosely assembled clot. This clot can then be used as an initial 
scaffold for tissue regeneration, serving as a platform for cell migration and proliferation. 
Fibrinogen has the ability to be an ideal tissue engineering scaffold, not only for it’s 
clotting properties, but also because it has the ability to bind with a wide array of 
molecules that could be beneficial from a vascular prosthetic engineering standpoint, 
such as vascular endothelial growth factor (VEGF). 
One way to create fibrin based scaffolds is through the process of electrospinning. 
The procedure of electrospinning is attractive to many research projects because it is a 
simple process that requires very little equipment but can provide a lot of end material 
and can be performed either in a laboratory or in scaled up production[10]. The process 
begins with a polymer solution drawn through a syringe needle and charged with an 
electric potential in varying kilovolts.  Once the solution reaches a critical electric 
potential, the solution jet is then collected at a target thrombin bath, which is placed a set 
distance away from the polymer solution, allowing for the crosslinking to occur. This 
work has been previously done to create aligned hydrogel microfibers from various 
natural polymers[18]. Electrospinning scaffolds is a good option for tissue engineering 
because the end product can be manipulated into a wide variety of shapes and can consist 
of fibers in an assortment of orientations. For the intent of these experiments we have 
chosen both a solid microfiber with an aligned internal and external nanotopography and 




Degradation by Plasmin  
Another important parameter to consider when using scaffolds created from 
biomaterials is degradation. More importantly, it is vital to determine if the scaffold is 
able to degrade in the body while leaving behind a freestanding tissue that can then adapt 
to the patient. Fibrin is degradable through a reaction with plasmin, an active version of 
the protein plasminogen[19]. The degradation process occurs when plasminogen is 
activated by tissue-type plasminogen activator or urokinase-type plasminogen 
activator[19-21]. The plasminogen is then cleaved to plasmin and then interacts with 
fibrin, thus degrading the fibrin into soluble fibrin degradation products regulated by  -
antiplasmin. 
It has been shown in many studies that vSMCs naturally produce plasminogen 
activators[19, 22]. This natural production allows for the cleavage of the plasmin to 
rapidly occur, and then the reaction between plasmin and fibrin ensues, leaving 
degradation products. 
Goals and Aim of Thesis 
The main goal of this series of experiments was to create free standing perfusable 
microvasculature. Previously our group was able to recreate multicellular microvascular 
tissue from ECFCs and vSMCs used. We used this to ensure the structural development 
is in the correct order. Because fibrin has the ability to degrade, the first aim was to fully 
degrade the fibrin scaffold and to obtain a luminal structure with a cell wall of 
appropriate thickness. The final aim was to create and develop a device that would help 
construct these robust structures. Once these microvascular structures were created and 
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Endothelial Colony Forming Cells (Lonza, Walkersville, MD) between passages 
six and nine were used for experiments and expanded in flasks coated with type I 
collagen (BD Biosciences, Franklin Lakes, NJ). The ECFCs were cultured in Endothelial 
Basal Medium 2 (EBM-2; Lonza) supplemented with EGM-2 Bulletkit (Lonza) and 10% 
fetal bovine serum (FBS; hyclone, Logan, UT) every other day. Once confluent, usually 
between three to five days, the cells were passaged with 0.05% trypsin/0.1% 
ethylenediaminetetraacetic acid (EDTA; Invitrogen, Carlsbad, CA). 
Human vascular smooth muscle cells (ATCC, Manassas, VA) between passages 
five and nine were used for experiments. The vSMCs were cultured and fed with F-12K 
medium (ATCC) supplemented with 0.01 mg/ml insulin (Akron Biotech, Boca Raton, 
FL), 10% fetal bovine serum (FBS; hyclone, Logan, UT), 0.05 mg/ml ascorbic acid, 0.01 
mg/ml transferrin, 10 ng/ml sodium selinate, 0.03 mg/ml endothelial cell growth 
supplement, 10 mM HEPES, and 10 mM TES (all from Sigma-Aldrich, St. Louis, MO). 
Fabrication of Three Dimensional Fibrin Hydrogel Microfibers 
Fabrication of the microfibers followed a similar protocol as described before, and 
were developed in collaboration with the Mao lab in the Material Science and 
Engineering Department at Johns Hopkins University [18]. There were two different 
types of microfibers used; fibrin and alginate microfibers and fibrin only microfibers.
1
 To 
                                                 
1
 All hollow fibers were fibrin only fibers. 
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create the microfibers, a 2 wt% fibrinogen solution is fed through a syringe at a feeding 
rate of 2 ml/h and in-line mixed with or without a 1.5 wt% alginate solution at 1 ml/h. 
The solution is electrospun by applying a 5 kV electric potential between the needle and 
the collecting plate. Resulting electrospun nanofibers are then collected in a rotating bath 
of 50 mM CaCl2 solution with 5 units/ml thrombin for twenty minutes to crosslink the 
fibrinogen, creating a ring-like sheet comprised of nanofibers. Once removed from the 
thrombin bath, the nanofibers are then soaked in 0.2 M sodium citrate overnight, 
transferred to water for 30 minutes, bundled into a microfiber, stretched, and air dried.  
Fabrication of Hollow Microfibers 
To fabricate hollow microfibers, the same method described above was used to 
create microfiber sheets by rastering the landing position of the fibrinogen jet on the 
collection solution.  Then these microfiber sheets are wrapped around a mandrel that has 
been coated with PTFE (Teflon; Applied Plastics Co., Norwood, MA). From there, the 
hollow fibers are soaked in a very high concentration thrombin bath (100 U/ml) to 
further crosslink between the wrap layers create a continuous structure.   Circumferential 
or longitudinal alignment of the fibrin structure is generated based on the orientation of 
the mandrel during wrap relative to the fiber sheet alignment. Once both the coiled coil 
and longitudinal structures are crosslinked, they are frozen and lyophilized, following 
which they are removed from the mandrels. 
Prior to seeding, the fibers are sterilized in 75% ethanol and rinsed twice with water. 
Cell Seeding and Culture on Fibrin Hydrogel Microfibers 
 Cell seeding on fibrin hydrogel microfibers follows the same procedure as 
described before[23]. Once ECFCs were confluent, they were passed and seeded on fibrin 
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hydrogel microfibers wrapped around custom made frames. Cells were passaged with 
0.05% trypsin/0.1% ethylenediaminetetraacetic acid (EDTA; Invitrogen, Carlsbad, CA) 
and then seeded to the microfibers at a cell density of 2x10
6
 cells in 4 to 5 ml of ECFC 
media supplemented with 50 ng/ml VEGF (Pierce, Rockford, IL) in custom made tubes. 
The tubes were then placed on a tumbler for twenty-four hours at 37˚C to allow cells to 
attach to the microfiber. Frames were then transferred to 35 mm dishes and cultured in 
ECFC media supplemented with VEGF for another four days with media changes every 
other day. On day five of the experiment, vSMCs were seeded onto the ECFC seeded 
microfibers in the same way; cells were seeded at a cell density of 2x10
6
 cells in 4 to 5 ml 
of regular ECFC media (no VEGF supplement) for another five days. Samples received a 
media change every other day. Ten days after the original ECFC seeding, samples were 
fixed and stained as described below. 
Cannulating of Conduit Fibers and Perfusion 
Conduit shaped fibers were cannulated using luer lock needles gauges 25 to 30. 
Once the fibers were secured with either surgical glue or sutures, diluted blue dye or 
media was directly perfused through the needles and fibers using a three port leur lock, 
where one port was attached to the needle, one was closed, and the third was attached to a 
syringe.  
Three Chamber Device Set Up, Cell Seeding and Culture on String Fibrin Microfibers 
Before setting up the device, all components, a glass slide cover, two screws and 
nuts, the top and bottom plate made of poly(methyl methacrylate) (PMMA), and six luer 
lock caps, were autoclaved to ensure sterility; significant pieces are shown in Figure 
1[24]. At the same time, two polydimethylsiloxane (PDMS) blocks were cut to the size 
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25 mm x 10 mm, with a slit cut 3 mm from the bottom of each block and polyester shrink 
tubing with an inner diameter of 250 µm was cut into 10, 8 mm long pieces. Five pieces 
of tubing was then placed parallel to one another throughout the slit at the bottom of each 
block with 2 to 3 mm left on either side. Once the tubing was fed through, the sides 
facing each other had that tubing coated in type I collagen for one hour. Once the allotted 
time was finished, five fibrin microfibers were then fed through the tubing of both blocks.  
 
 
Figure 1: Three Chamber Device Set Up showing the (A) top and (B) bottom plates separately. Three 
chamber device set up after a cell seeding is shown in (C). The device consisted of two plates placed onto 
each other with a small chamber cut out in the center of each plate. The plates were secured with vacuum 
grease to ensure a seal. Additionally, two nuts and bolts were used to keep the plates in place and four 
binder clips were placed on each side of the device to make sure the plates stayed together. (D) The bottom 
of the three chamber device shows how the PDMS blocks create the three distinct chambers. 
To assemble the device, all components along with the PDMS – fiber bridge were 
brought into the biological safety cabinet. Vacuum grease was applied to the interface of 
the two plates, leaving a 1 cm gap from the inner chamber of the device on both plates. 
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Additionally, vacuum grease was applied to the bottom of the glass cover slip and then 
the side that was coated was placed in the inner compartment of the bottom plate and 
pressed firmly around the edges to confirm a seal. Once everything has been coated with 
vacuum grease, all parts including the PDMS – fiber bridge were then UVed for 30-45 
minutes. The blocks with the fibers were then placed on the center of the glass cover slip. 
The fibers were then pulled taut and trimmed to ensure the smallest amount of fiber and 
tubing combination was in the outer compartments. Then, sterile water was placed in the 
center compartment to help hydrate the fibers, ensuring they swell in the tubing and 
remain taut and stable throughout the length of the experiment. The device was sealed by 
pressing the two plates together firmly, screwing in the screws, and sterilizing with 75% 
ethanol and rinsed with sterile water three times via luer lock ports. Leaving some water 
in the middle compartment to prevent microfiber dehydration, the device was then placed 
in a 37˚C incubator overnight to ensure a vacuum seal. The next morning, the exterior 
compartments are filled with phosphate buffered saline (PBS) throughout the duration of 
the experiment. 
Cell seeding on fibrin fibers followed the protocol described above. ECFCs were 
seeded to the middle compartment of the device at a cell density of 2x10
6
 cells in 3 ml of 
ECFC media supplemented with 50 ng/ml of VEGF. The device was then secured to a 
tumbler for twenty-four ours at 37˚C to facilitate cell adhesion. Media was changed every 
other day for five days. On day five of the experiment, vSMCs were then seeded to the 
center compartment that contained the ECFC seeded microfibers at a cell density of 
2x10
6
 cells/ml with ECFC media. The device was once again attached to the tumbler at 
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37˚C for another twenty-four hours with media changed every other day for another ten 
to fifteen days. Overview of the entire experiment is shown in Figure 2. 
 
Figure 2: Time Frame for Cell Seeding for Microvasculature Reconstruction 
Single-Chamber Device Set Up, Cell Seeding and Culture on Conduit Fibrin Microfibers 
Before setting up, borosilicate tubing (Friedrich and Dimmock Glass, Millvile, 
NJ) with dimensions 13 mm x 26 mm cut in 38 mm pieces were sonicated and then 
autoclaved to ensure sterility. Simultaneously two PDMS blocks were cut to 15.5 mm x 
24 mm. A one inch 25 gauge blunt tip luer lock needle was then punctured 3 mm from 
the bottom of both PDMS blocks and at the top left corner of each block, a size 14 gauge 
blunt tip luer lock needle was punctured through both blocks as well.  The conduit fibers 
were then cannulated and sutured between the two 25 gauge needles as show in Figure 3.  
The set up was then moved to the biological safety cabinet, where ethanol was added to 
fill the entire chamber using the size 14 gauge needle at the top corner. Once the chamber 
was filled, the system was further sterilized by UV treatment for 30 minutes. Afterwards, 
the chamber was washed with sterile distilled water three times via the top luer lock 
needle. The bottom needles were locked until the end of the experiment when perfusion 
takes place. 
 



















Figure 3: Design of Single Chamber Device (not drawn to scale) 
 
Cell seeding on conduit fibers followed same protocol described for the three chamber 
device.  
Degradation of Fibrin Microfibers 
 Microfibers with or without cells were treated with plasmin at 15, 1, 0.25, and 0.1 
CU/ml (Athens Research and Technology, Athens, GA) in Dulbecco’s Modified Eagle 
Medium (DMEM; Life Technologies, Carlsbad, CA) for 1, 6, 12, and 24 hours, 
respectively, and monitored regularly. Conduit fibers without any cells attached were 
treated with 0.25 CU/ml plasmin and DMEM for 12 hours.  
Plasmin Treatment in Three Chamber Device 
At day two of the experiment using the three chamber device, the outer 
compartments were treated with a degradation media consisting of 9 µg/ml of plasmin 
(equivalent to about 0.25 CU/ml), in DMEM that was changed every five days. At day 
twenty the inner compartment was treated with the same degradation media as the outer 
compartments, and media was refreshed every 12 hours.  
Immunofluorescence Staining and Confocal Microscopy 
Cell-microfiber samples were fixed with 3.7% formaldehyde (Fisher Chemicals, 
Fairlawn, NJ) for fifteen minutes, permeabilized with 0.1% Triton X-100 (Sigma 
 14 
Aldrich) solution for ten minutes, and then blocked with 0.01% bovine serum albumin 
(Sigma Aldrich) for one hour. After washing the sample three times with PBS, primary 
antibodies were then added to the samples and incubated for one hour at the dilutions 
shown in Table 1. After another three washes of PBS, samples were incubated with 
secondary antibodies, Alexa Fluor 546, and Alexa Fluor 647 (Invitrogen), or conjugated 
phalloidin (Invitrogen) at room temperature for one hour. Samples were washed with 
PBS another three times and then counterstained with DAPI for ten minutes. Z-stack 
images were taken using confocal microscopy (LSM 780 Carl Zeiss Inc., Thornwood, 
NY) in order to further analyze samples. 
 
 
Table 1: Immunofluorescence Dilutions used during staining of microvasculature samples constructed. 
Results 
Development of Microvascular Structures on Frames 
 Previously our group devised a protocol to develop microvasculature using fibrin 
microfibers [23]. We seeded ECFCs onto microfibers wrapped around frames for five 
days followed by vSMCs for another five days. These samples were then fixed and 
stained for various ECM proteins to show their organization and ensure cell alignment 
along the string-like microfiber. Microfibers wrapped around frames were then degraded 
Reagent Type Name Host Dilution Used 
Primary Antibodies 
Type IV Collagen Mouse/Rabbit 1:100 
Fibronectin Rabbit 1:100 
Elastin Mouse 1:100 
VECad Mouse 1:100 
SM22 Rabbit 1:100 
Secondary Antibody 
Alexa 546 Donkey 1:500 
Alexa 647 Donkey 1:500 
Conjugated 
Antibody 
Phalloidin 488 Shroom 1:50 
DAPI N/A 1:1000 
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to create multicellular structures with a lumen after the ten day culture period. However, 
we wanted to develop a more robust smooth muscle cellular layer that would withstand 
perfusion. To do this we extended the vSMC culture time from five days to ten to fifteen 
days. 
Degradation Studies to Remove Fibrin Core 
To be able to use the microvasculature created it was necessary to begin 
degradation studies of the scaffolds. We begun by treating the fibrin and alginate-fibrin 
microfibers with different concentrations of plasmin. We found that plasmin based 
degradation is concentration dependent as shown in Figure 4. We treated microfibers 
with concentrations of 15, 1, 0.25, and 0.1 CU/ml plasmin, which degraded the 
microfibers in 1, 3, 6, 12, and 24 hours respectively. From the different concentrations, 
we determined that 0.25 CU/ml plasmin treatment for 12 hours and the 0.1 CU/ml 
plasmin treatment for 24 hours were the most suitable for the experiments to follow. The 
12 and 24 hour treatments were also performed on microfibers made from fibrin only (no 
alginate) as shown in Figure 5. 
 
 
Figure 4: Fibrin-Alginate hydrogel microfiber degradation using a plasmin treatment with various 





Figure 5: Fibrin only hydrogel microfiber plasmin degradation with plasmin concentrations of 0.25 and 0.1 
CU/mL for 12 and 24 hours respectively. Scale bar = 100 µm. 
Once it was established that degradation of the scaffold was possible, we 
conducted experiments to see how the plasmin degradation media would affect the cell 
layers cultured onto the microfibers. We seeded ECFCs onto microfibers wrapped around 
frames for five days followed by vSMCs for another five days. After the ten days, we 
fixed, stained, and imaged samples and then administered a 0.25 CU/ml plasmin 
treatment on the microvascular structures for 12 hours. This showed that the plasmin 
treatment would not affect the cell layers and keep the ECM organization intact. After 
treatment, we analyzed the samples for degradation of fibrin microfibers as well as lumen 
formation. Using confocal imaging, we found that each cell layer was still intact after the 
plasmin treatments as shown in Figure 6. Immunofluorescence staining of the structures 
revealed a large deposition of various ECM proteins such as elastin, and fibronectin. 
Because we could not achieve full degradation of the fibrin-alginate core, we used fibrin-
only microfibers for the remainder of the study. 
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Figure 6: Initial degradation studies on frames: ECFCs were seeded and cultured onto fibrin-alginate 
microfibers for five days followed by vSMC which were cultured for another five days on frames. The 
samples were then fixed and stained for elastin (red), fibronectin (magenta), f-actin (green), and nuclei 
(blue). Cocultures then went through a degradation treatment of 0.25 CU/mL plasmin for 12 hours and 
reimaged to see if the cell layers were affected. Scale bars = 100 µm. 
 
Live Cell Culture on Microfiber and Degradation on Frames 
After demonstrating that the cell layers would not be affected by the plasmin 
treatment when tested on frames, we then decided to first test the plasmin treatment on a 
live cell culture using the frame set up. We cultured ECFCs on fibrin only microfibers on 
frames for five days followed by vSMCs for another fifteen days. After cells were 
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cultured for twenty days, we administered 12 hour treatments of 0.25 CU/ml plasmin 
media to live co-cultures followed by a 12 hour recovery in regular culture media up to a 
total of four cycles. 
 
 
Figure 7: Brightfield images of live cell culture degradation: ECFCs were seeded onto fibrin only 
microfibers for five days followed by vSMCs were then cultured for another fifteen days on frames. 
Microvasculature cell culture on fibrin only microfibers were then given a degradation treatment for 12 
hours with 0.25 CU/mL plasmin and then immediately given a twelve hour recovery period with full serum 
ECFC media. This was repeated four times to demonstrate that the microfiber was able to degrade while 
cells were attached. Scale bar = 100 µm. 
We found that after one treatment of degradation media, a portion of the 
microfiber had degraded indicating that fibrinolysis had occurred. Additionally, a greater 
amount of fibrin degraded with each administration of the plasmin treatment. Figure 7 
shows the progressional degradation of the fibrin microfiber after each round of plasmin 
treatment with twelve-hour recovery periods in ECFC culture media. Afterwards, we 
fixed and stained samples for F-actin, type IV Collagen and Elastin, and then imaged 




Figure 8: Microvasculature with a fully degraded fibrin core: ECFCs were seeded onto fibrin only 
microfibers for five days followed by vSMCs were then cultured for another fifteen days on frames. 
Microvasculature cell culture on fibrin only microfibers were given a degradation treatment for 12 hours 
with 0.25 CU/mL plasmin and then immediately given a twelve hour recovery period with culture media 
four times. Sample was then fixed and stained for type IV collagen (magenta), elastin (red), f-actin (green), 
and nuclei (blue). This demonstrated that it was possible to fully degrade the fibrin-only fiber leaving a 
lumen as shown above. Scale bar = 100 µm. 
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The degradation of the fibrin microfiber demonstrated that it was possible to 
break down the scaffold and lead to partial lumen formation. However, the structure 
constructed also began to collapse due to SMC contraction in the absence of flow. This 
gave us motivation to create a device that would allow us to perfuse the developing 
structures immediately following fibrin core degradation. 
Three Chamber Device 
After the success of the previous experiments on frames, we created a device to 
construct freestanding microvasculature, which would then have the fibrin microfiber 
core degraded, allowing perfusion of fluids through the new structures. A three-chamber 
device was created to allow the construction of freestanding microvasculature as shown 
in Figure 1. The device consists of two PMMA plates placed onto each other with a small 
PMMA chamber cut out in the center of each plate. The plates were secured with vacuum 
grease to ensure a seal. Additionally, we used two nuts and bolts to keep the plates in 
place and then placed four binder clips on each side of the device to make sure the plates 
stayed together. To create the three chambers, two blocks made of polydimethylsiloxane 
(PDMS) were evenly separated throughout the chamber. The PDMS blocks then held up 
the microfibers, so that individual scaffold samples did not rely on other samples to stay 
taught and straight throughout the experiment. 
We first seeded ECFCs onto the microfibers in the inner chamber of the device 
for five days. Following this, vSMCs were seeded on top of the ECFCs and then cultured 
for another 15 days. At day twenty of the experiment, we placed degradation media (0.25 
CU/ml plasmin in DMEM) in the two outer chambers for the remaining of the experiment 
to allow degradation of the microfibers. After the allotted vSMC culture had elapsed, we 
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administered four rounds of plasmin degradation treatment to the inner compartment. 
After each degradation treatment, the samples had a 12 hour recovery in culture media. 
When we established a protocol to create the microvasculature within the inner 
compartment of the chamber, we still had many issues with fully degrading the fibrin 
scaffold within the inner compartment. 
 
 
Figure 9: Progression of Fibrin Core Degradation in the Three Chamber Device: ECFCs were cultured onto 
fibrin only microfibers for five days followed by vSMCs for another fifteen days in the three-compartment 
device. Samples were administered the degradation plasmin treatment of throughout the experiment in both 
(A) the two outer compartments and (B) the inner compartment. The degradation process began on day 2 
for the outer compartments and at day 20 for the inner compartment with 0.25 CU/ml plasmin with 
DMEM. For the inner compartment plasmin treatment was administered for twelve hours with a twelve-
hour recovery period in full serum ECFC media; this process was repeated three times. Scale bar = 100 µm. 
To improve degradation in the device, we started degradation treatments in the 
two outer compartments at day two of the experiment; changing the degradation media 
every five to six days. These changes resulted in the microfibers degrading faster in the 
outer compartments, as shown in the bright field images of the progression of the 
degradation treatments in Figure 9. Although the amount of fibrin microfiber degraded 
had increased from the previous experiments, the thicker cell layer resulting from longer 
culture periods prevented full microfiber core degradation and subsequent lumen 
formation. We then fixed, stained, and imaged samples for deposition of ECM proteins  




Figure 10: Microvasculature with partially degraded fibrin core: Samples in three chamber device were 
ECFCs cultured on fibrin only microfibers for five days followed by vSMCs cultured on the microfibers for 
another fifteen days. Samples were then administered four rounds of degradation media immediately 
followed by a twelve hour recovery period in culture media. Microvasculature was then fixed and stained 
for type IV collagen (magenta), elastin (red), f-actin (green), and nuclei (blue) after 20 days of cell culture, 
shown in (A) 10x magnification (Scale Bar = 1 mm) and (B) 20x magnification (Scale Bar = 100 µm).  
Another method that we attempted to increase the amount of fibrin microfiber 
degradation was to shorten the size of the microfiber used for the scaffold of the 
microvascular structures. This is because the smaller the amount of material used, the 
faster the degradation of the scaffold. Combining the two techniques proposed a way to 
optimize the amount of microfiber degradation in the device. However, as shown by 
Figure 11, this attempt was also unsuccessful, demonstrating the exact opposite of what 
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we hypothesized. Even less of the material was degraded than the previous two runs of 
the experiment. We fixed and stained the structures to show the endothelial cell and 
vSMC structure with vascular endothelial cadherin and vSMC marker SM22 to 
demonstrate how the two cell types lay upon each other on the scaffold; this is shown in 
Figure 12.  We found that there was no vascular endothelial cadherin expression, 
demonstrating that the vSMCs did not reorganize the cellular layers. 
 
 
Figure 11: Second Experiment in Three Chamber Device: ECFCs were cultured onto fibrin only 
microfibers for five days followed by vSMCs for another twenty days in the three-compartment device. 
Samples were administered the degradation plasmin treatment (0.25 CU/ml plasmin in DMEM) in the inner 
compartment beginning at day 20. A twelve-hour recovery period in full serum ECFC media was given 
immediately after the twelve-hour treatment; this process was repeated three times. This run of the three 
chamber device used the smallest possible length of microfiber scaffold to see if full degradation was 
possible in the device similar to that of on the frame. Scale bar = 100 µm. 
 
 
Figure 12: Endothelial Cell and Smooth Muscle Cell positioning of microvasculature: Samples in three 
chamber device were ECFCs cultured on fibrin only microfibers for five days followed by vSMCs cultured 
on the microfibers for another twenty days. Samples were then administered four rounds of degradation 
media immediately followed by a twelve hour recovery period in full serum ECFC media. 
Microvasculature created were then fixed and stained for SM22 (magenta), f-actin (green), and nuclei 
(blue) after 25 days of cell culture. This demonstrated that the SMCs and ECFCs did not move around, but 
stayed in the three layers of microvasculature. Scale bar = 100 µm. 
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We were unable to obtain full degradation of the fibrin only microfibers in this set 
up due to plasmin diffusion through the thick cell layer, as well as fibrinolysis products 
being stuck inside the lumen that was created. Based on the three unsuccessful attempts, 
we designed a new system and microfiber shape to be one step closer to the main goal of 
creating perfusable freestanding microvascular structures. 
Introduction of Conduit Hollow Fibers 
While troubleshooting the three chamber device, the first component that we 
changed was to alter from cylindrical microfibers to hollow conduit microfibers. We 
fabricated the hollow microfibers of the same material as the microfibers; fibrin. The 
main difference between the two is that there is a lumen in which fibrinolysis products 
can leave. 
First, we treated the hollow microfiber samples without cells with 0.25 CU/ml 
plasmin degradation media for 24 hours as shown in Figure 13. This was to demonstrate 
that the hollow microfibers were able to fully degrade similarly to regular microfibers. 
 
 
Figure 13: Coiled fibrin only hydrogel microfiber degradation using a 0.25 CU/mL plasmin treatment for 
12 hours. Scale bar = 500 µm. 
The most significant aspect of this particular shape was to ensure that there was 
no leaking while perfusing through the hollow fibers. We implemented three different 
methods of attaching the hollow microfibers to blunt needles for perfusion:  keeping the 
hollow fibers un-tethered, using surgical glue to fix them to the needles, and finally 
suturing the ends of the hollow fiber to the needles, anchoring them in a stable position. 
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We found that leaving the hollow microfibers un-tethered resulted in fibers falling off or 
leakiness at the ends of the fiber where it was attached to the needle. We also found the 
microfibers were absorbent to surgical glue, making its use undesirable. Meanwhile, 
sutures allowed the ends of the microfibers to be well anchored on the needles so they 
would not fall off during the twenty four hour tumble period of each cell seeding. 
Furthermore, there was minimal leaking at the ends when perfusing the microfibers 
without cells. After many trials we determined that suturing the microfibers was the best 
option.  
One Chamber Device 
When it was established that the new hollow fibers would not move from the 
needle, we created a single chamber device based on the design of the three chamber 
device. We utilized one inch pieces of borosilicate tubing as the chamber, and PDMS 
blocks capped the ends of the tubing. Each block holds two luer locks, one for media 
changes and the other for hollow microfiber perfusion. The hollow fiber is connected to 
the luer lock needles on both sides and secured with sutures to ensure that it will not fall 





Figure 14: Single chamber device set up  with conduit coil style hollow fiber sutured to luer lock needles. 
 We then conducted a trial experiment with ECFCs for five days to see if having a 
cell layer would prevent leaking.  We then fixed and stained the samples for F-actin, type 
IV Collagen, and Fibronectin to determine if the cell or ECM organization had changed 
at all due to the change of topography of the coil like hollow fiber, as shown in Figure 15. 
After confocal imaging, the structure demonstrated that the coil topography slightly 
changed the cell alignment of the ECFCs compared to that of the microfibers, which had 
previously shown to follow the longitudinal topography of the microfibers. We then 
perfused the structure with a fluorescent dye and demonstrated that a more robust cell 
layer was needed before perfusion could take place.  
 
 
Figure 15: Initial experiment with coiled style hollow fiber with ECFCs seeded on them for five days in 
single compartment device. Samples were then fixed and stained for type IV collagen (red), fibronectin 
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(magenta), and f-actin (green). The blue stain is to show the topography of the microfiber, demonstrating 
that the cells adhere to the ridges of the coils, instead of aligning along the fiber itself. Hollow microfibers 
are also twice as large as the microfibers. Scale Bar = 500 µm. 
We conducted another set of experiments with ECFCs cultured on the hollow 
fibers for five days. We also fixed and stained the structures for F-actin, Type IV 
Collagen and Fibronectin to see if the topography was similar to that in Figure 16. As 
shown in Figure 16, we found that the ECM was able to align perpendicular to the 
longitudinal axis of the microfiber and the alignment cues of the microfibers took 
precedence instead of the ridges in the topography of the microfiber. After imaging, we 
perfused the structure with DMEM to ensure minimal leakage from the structure and 
found that the microvasculature we created was able to perfuse media with a small 
amount leaking through. 
 
 
Figure 16: Second experiment of hollow fibers with ECFCs cultured for five days in single compartment 
device. Samples were then fixed and stained for type IV collagen (red), fibronectin (magenta), and f-actin 
(green). Scale Bar = 500 µm. 
Discussion 
The overall goal of this study was to create free standing perfusable microvascular 
structures from a fibrin microfiber scaffold. The first significant step towards this aim 
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was to create structures that mimicked each layer of microvasculature. Previously our 
group had shown that it was possible to create a scaffold that would incorporate 
alignment topography. This would ultimately help cellular organization, as well as how 
both the endothelial cells and vascular smooth muscle cells used would adhere and align 
to the fibrin scaffold and produce an optimal ECM deposition[18, 23, 25]. Furthermore, 
this system was shown to be able to recapitulate the wrapping ECM deposition 
surrounding the endothelium, as seen in native blood vessels. Additionally our group 
demonstrated that it was possible to create a multicellular microvascular structure with a 
lumen, however the culture time for these structures was only ten days total[25]. 
Additionally, these results were based on the microfibers that were held up by frames to 
maintain a taut, straight, foundation for the cells. Due to the success of these experiments 
we proceeded to construct a more robust tunica media, degrade the microfiber core, and 
continue maturation by applying flow. 
To degrade the fibrin microfiber scaffold, it was pertinent that the proper 
concentration of plasmin and time was used to find the optimal conditions that would 
allow the fibrin to go through fibrinolysis without killing too many of the cells. We chose 
the 12 hour treatment as the best choice because it allowed a long timeframe for the 
plasmin to interact with the fibrin without creating a cytotoxic environment for the cells. 
Because we were able to optimize how much plasmin to use for degradation and for how 
long, we tested fixed samples for the potential degradation of the cellular layer on the 
microfibers. To ensure the cellular layer was not destroyed, we used confocal imaging to 
demonstrate that each layer was in tact as well as various ECM proteins. However, we 
were unable to fully degrade the fibrin core from the fibrin-alginate microfibers at longer 
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time points. We then chose fibrin-only microfibers for the remainder of the experiments 
because the degradation of the scaffold was much more apparent in comparison to the 
fibrin-alginate microfibers.   
Once we found that cell and ECM layers remained intact after plasmin treatment, 
we moved to a live system to show the progression of degradation. These samples 
demonstrated that the scaffold could fully degrade in shorter culture time points. In 
addition, the first live cell culture degradation treatments on the scaffold wrapped around 
frames ensured that it was possible for the plasmin to pass through a thick cell layer and 
interact with the fibrin microfiber. Because we were able to degrade majority of the fibrin 
scaffold from microvasculature constructed, we determined that the cell construct could 
be moved to another system to progress closer to the goal. 
After the live cell structures experiments, we moved to a new setup that gave us 
the ability to perfuse though the microfibers after degradation treatments. With this new 
system we were able to give a new foundation for the construction of the microvascular 
structures. As each different round of experiments passed, we made small changes from 
round to round to help improve the degradation process. The first experiment 
demonstrated that the degradation process was not robust enough in the three 
compartment device. This lead to the following experiment where we began fibrinolysis 
on the outer compartments earlier than originally planned, at day two. We used an earlier 
degradation to try to create a smaller amount of the fibrin core that needed to be degraded 
later on in the experiment. Yet, this small step was still found to not be robust enough for 
full luminal formation and led to another suggestion; to shorten the length of the scaffold. 
Finally when the third round of experiments was done, we used the smallest possible 
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length of microfiber possible to help achieve full degradation. However when we were 
unable to create a lumen after beginning degradation at day two and used a smaller 
amount of the scaffold, we determined that it would be best to change to another set up. 
One possible reason that the degradation did not occur as smoothly as the structures on 
the frames is that the cellular layer was too thick; it could have inhibited the plasmin 
diffuse through the structure created. Another reason is that the fibrin degradation 
products had nowhere to go but within the newly formed lumen, and therefore we could 
not engineer a perfusable microvascular structure. 
After demonstrating that full degradation was not possible in the three chamber 
device, even after the two modifications we changed a few important parts of the set up. 
The main change we made was to alter the microfiber shape. In collaboration with the 
Mao lab and their PhD candidate Brian Ginn, we fabricated a new shape for the scaffolds 
that were used for the rest of the study. We interchanged the original microfibers for a 
hollow tube shape to obtain direct perfusion instead of indirect. This shape did not have 
to rely on degradation treatments for luminal formation because this new shape already 
possessed one. Initially, we fabricated the coiled microfibers with coils of fibrin onto 
regular mandrels. However, when we found many leaking issues from this fabrication 
method, we switched to PTFE coated mandrels and used them along with sheets of fibrin 
to fabricate the hollow microfibers. We analyzed several different scaffold preparation 
methods. The first being the style of how the microfiber sheets are wrapped around the 
PTFE mandrel: longitudinal or coiled coil or a combination of the two. For initial 
experiments, we used coiled hollow microfibers due to the ease in fabrication. The 
second preparation method we chose was the dehydration process used after the hollow 
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microfibers were fabricated and frozen; vaporized, vaporized and lyophilized, and 
lyophilized. Initial experiments showed vaporized microfibers were not suitable because 
they were problematic when we tried to perfuse them. This is because during the 
vaporization process, the walls of the fibers began to puff up, creating blockages 
throughout and ultimately not creating a clear lumen. We tried to cannulate the scaffolds 
with a needle before rehydration and perfusion to clear a pathway. However, this did not 
help because either the microfibers would break when attempting cannulation or when we 
rehydrated the microfiber, the blocked lumen reappeared. Ultimately, lyophilized was 
chosen because when we rehydrated the microfibers, these scaffolds were able to perfuse 
media through with no issues.  
Once the technique for hollow microfiber fabrication was chosen, the next 
important step we considered was whether it was possible to perfuse through the scaffold 
without any leaking. Two methods were attempted to ensure no leaking; surgical glue and 
sutures. The first that was attempted was surgical glue. From the beginning trials, we 
showed that the fiber needed to be rehydrated before the glue could be used. Otherwise 
the scaffold would use the liquid glue to hydrate itself. Another characteristic that should 
be noted is that even after rehydration, when the surgical glue was placed on the 
microfiber, it would become stiff and brittle from the glue. This itself was a problem 
because of the potential cytotoxic effects that could harm the cells; not giving the cells 
enough of a stable foundation to adhere and proliferate to instead of just adhering and 
dying. 
When it was determined surgical glue was not the correct choice, we attempted to 
use sutures to prevent leaking from the scaffold. We determined that sutures were the 
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best choice because they allowed a tight seal between the needle that the hollow fiber was 
resting on and the microfiber itself, decreasing the chances for leaking in the scaffold. In 
addition to this we created a more minimal system to run in parallel to the three chamber 
device. This setup focused on the inner chamber where the structures were constructed 
and allowed for a direct perfusion of the structures. The one chamber device also allowed 
for many experiments to run parallel to each other, giving more time to troubleshoot and 
fix problems being faced during experimentation. 
We conducted an initial experiment with ECFCs cultured on the coiled hollow 
microfiber five days to see if the deposition of ECM and ECFC alignment had changed. 
Additionally we attempted to perfuse through the structure created to show if perfusion 
without leaking was possible with the allotted time for cell growth. It was clear that the 
topography of the hollow microfiber had slightly changed the formation of the ECM and 
the cell alignment. Instead of the cells aligning around the microfiber in an organized 
fashion, the cells followed the ridges of each of the coils. Due to this, a non-uniform layer 
of cells and ECM was formed and ridges were seen. This can create potential issue for 
long term perfusion because surface topographic features, such as the ridges, can impact 
the behavior of the endothelial cells[26, 27]. To ensure that the topographic features of 
the hollow microfibers did not affect the wrapping of ECM proteins, we ran two more 
experiments in parallel of ECFCs for five days. These experiments demonstrated that the 
cells followed a similar style adhesion and alignment that was previously seen with the 
microfibers;. Additionally, from these experiments we were able to perfuse DMEM 
through the five day structure with minimal leaking. This encouraged for the progression 
to begin vSMC culture in addition to the ECFC culture to create a robust cellular layer. 
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Conclusion 
This study demonstrates the progression of vessel development from a fibrin 
hydrogel microfiber to a perfusable vascular structure. Each step in the progression lead 
to another new accomplishment towards the final goal; from wrapping the fibers on 
frames, to setting up different devices for freestanding structures, to creating perfusable 
structures with no leaking. We were able to determine that it is possible to create vascular 
structures from the scaffold, with the tunica intima and media layers of the 
microvasculature clearly created and seen via confocal imaging. Additionally, the ECM 
deposition from the coculture is significantly larger than previously seen due to a longer 
culture period. This demonstrates that the device style experiments allowed the structures 
to not have as much contact while changing media, and therefore increasing the 
possibility of polymerization of ECM proteins. Finally, the last experiments in the study 
demonstrated that it is possible to obtain perfusable microvasculature using the single-
chamber device and hollow microfiber shape. 
For future experiments, first we will begin with the cocultures of ECFCs and 
SMCs for a twenty day experiment to create a thick cell layer. Once this cell layer is 
created, we will perfuse the microvasculature created with either a syringe or a peristaltic 
pump from anywhere between a few minutes to a few days. Other various adjustments 
could be considered to help create a stable system that results in the freestanding 
microvasculature we aim to construct. One possible alternative is to encapsulate plasmin 
within the fibrin microfibers to help increase the degradation rate. This adjustment would 
be used for both the microfibers and hollow shaped microfibers. Additionally, with this 
alternative, we would be able to use both microfiber shapes for both the three chamber 
and one chamber devices used throughout this study to achieve the maximum amount of 
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vascular structures. Another possible adjustment that could be made is to seed endothelial 
cells on the inside of the hollow microfibers while culturing vSMCs on the outside. We 
would then perfuse media through the hollow fibers in addition to the normal media 
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